"
Team:EPF-Lausanne/Our Project/TetR mutants/Conclusion
From 2011.igem.org
| (6 intermediate revisions not shown) | |||
| Line 9: | Line 9: | ||
!| Affinity compared to WT - in vivo | !| Affinity compared to WT - in vivo | ||
!| Affinity compared to WT - MITOMI | !| Affinity compared to WT - MITOMI | ||
| - | |||
|- | |- | ||
| V36F | | V36F | ||
| Line 15: | Line 14: | ||
| same | | same | ||
| higher | | higher | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
|- | |- | ||
| E37A W43S T141A | | E37A W43S T141A | ||
| <html> <a href="http://partsregistry.org/Part:BBa_K613015"> BBa_K613015</a> </html> | | <html> <a href="http://partsregistry.org/Part:BBa_K613015"> BBa_K613015</a> </html> | ||
| same | | same | ||
| - | |||
| altered | | altered | ||
|- | |- | ||
| Line 32: | Line 23: | ||
| <html> <a href="http://partsregistry.org/Part:BBa_K613016"> BBa_K613016</a> </html> | | <html> <a href="http://partsregistry.org/Part:BBa_K613016"> BBa_K613016</a> </html> | ||
| no affinity | | no affinity | ||
| - | | | + | | no affinity |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
| P39Q Y42M | | P39Q Y42M | ||
| Line 45: | Line 29: | ||
| no affinity | | no affinity | ||
| not tested | | not tested | ||
| - | |||
|} | |} | ||
| + | |||
| + | |||
| + | The '''P39K mutant''' shows in both cases (''in vivo'' and ''in vitro'') no affinity to the Ptet consensus sequence, showing that our results are consistent between the two characterizations. | ||
| + | |||
| + | The '''V36F mutant''' either shows a stronger or a similar binding affinity compared to the WT. The differences not being striking, our characterization methods are here again consistent, with the ''in vitro'' technique being more sensitive than the ''in vivo''. | ||
| + | |||
| + | Finally, the '''E37A W43S T141A triple mutant''' was shown ''in vitro'' to have a different consensus sequence that the wild-type Ptet sequence. However, the ''in vivo'' experiment only tested the mutant with the wild-type Ptet and shows an affinity in the range of the wild-type TetR. These two results indicate that, althoud a change in specificity, there is still crosstalk with the original Ptet sequence. This mutant is the most promising of the three characterized in our two systems, harbouring a change in specificity as well as DNA binding properties. Still, this is not an orthogonal mutant; more TetRs need to be tested before fully eliminating crosstalk with wild-type Ptet. | ||
| + | |||
| + | |||
| + | The results coming from the ''in vivo'' and ''in vitro'' part are consistently related. We have tested only 3 mutants in both systems ; we would need more characterization results to improve our selection systems, especially the ''in vivo'' part. | ||
The MITOMI results can be found [https://2011.igem.org/Team:EPF-Lausanne/Our_Project/TetR_mutants/MITOMI_data here]. The in vivo characterizations are on [https://2011.igem.org/Team:EPF-Lausanne/Our_Project/Reporter_Systems/tetR#TetR_mutant_characterization this page]. | The MITOMI results can be found [https://2011.igem.org/Team:EPF-Lausanne/Our_Project/TetR_mutants/MITOMI_data here]. The in vivo characterizations are on [https://2011.igem.org/Team:EPF-Lausanne/Our_Project/Reporter_Systems/tetR#TetR_mutant_characterization this page]. | ||
Latest revision as of 19:39, 26 October 2011
In Vivo & In Vitro Outline
In vitro Main | Why TetR? | Mutant TetRs | MITOMI Data | In-vivo & In-vitro outline
For some of the TetR mutants, we managed to have both an in vitro and in vivo characterization. The results are available in the table below.
| Mutant | Biobrick number | Affinity compared to WT - in vivo | Affinity compared to WT - MITOMI |
|---|---|---|---|
| V36F | BBa_K613013 | same | higher |
| E37A W43S T141A | BBa_K613015 | same | altered |
| P39K | BBa_K613016 | no affinity | no affinity |
| P39Q Y42M | BBa_K613019 | no affinity | not tested |
The P39K mutant shows in both cases (in vivo and in vitro) no affinity to the Ptet consensus sequence, showing that our results are consistent between the two characterizations.
The V36F mutant either shows a stronger or a similar binding affinity compared to the WT. The differences not being striking, our characterization methods are here again consistent, with the in vitro technique being more sensitive than the in vivo.
Finally, the E37A W43S T141A triple mutant was shown in vitro to have a different consensus sequence that the wild-type Ptet sequence. However, the in vivo experiment only tested the mutant with the wild-type Ptet and shows an affinity in the range of the wild-type TetR. These two results indicate that, althoud a change in specificity, there is still crosstalk with the original Ptet sequence. This mutant is the most promising of the three characterized in our two systems, harbouring a change in specificity as well as DNA binding properties. Still, this is not an orthogonal mutant; more TetRs need to be tested before fully eliminating crosstalk with wild-type Ptet.
The results coming from the in vivo and in vitro part are consistently related. We have tested only 3 mutants in both systems ; we would need more characterization results to improve our selection systems, especially the in vivo part.
The MITOMI results can be found here. The in vivo characterizations are on this page.
